Heterogeneity in physician and patient preferences for the treatment of renal cell carcinoma: Evidence from latent class analysis.

被引：0
|
作者：
Vass, Caroline
Pinto, Cathy Anne
Myers, Kelley
Imai, Kentaro
Bussberg, Cooper
Bhattacharya, Rituparna
Calhoun, Shawna R.
Poulos, Christine
机构：
[1] RTI Hlth Solut, Manchester, England
[2] Merck & Co Inc, Rahway, NJ USA
[3] RTI Hlth Solut, Res Triangle Pk, NC USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
661
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Nivolumab treatment for patients with non-clear cell renal cell carcinoma: A multicenter retrospective analysis.
    Koshkin, Vadim S.
    Barata, Pedro C.
    Vogelzang, Nicholas J.
    Pal, Sumanta K.
    Hsu, Joann
    Allman, Kimberly D.
    Gilligan, Timothy D.
    Rini, Brian I.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [22] TREATMENT OF ADVANCED RENAL CELL CARCINOMA IN SPAIN: ONCOLOGISTS' PREFERENCES
    Lazaro-Quintela, M.
    Crespo, G.
    Soto de Prado, D.
    Blasco, S.
    Gomez de Liano, A.
    Basterretxea, L.
    Etxaniz, O.
    Gabas Rivera, C.
    Aceituno, S.
    Polanco Sanchez, C.
    Lopez-Martin, M.
    Fernandez, O.
    VALUE IN HEALTH, 2020, 23 : S471 - S471
  • [23] PATIENT BENEFIT-RISK PREFERENCES FOR ADVANCED RENAL CELL CARCINOMA TREATMENTS: RESULTS FROM A CONJOINT ANALYSIS STUDY
    Mohamed, A.
    Yang, J. C.
    Hauber, A. B.
    Liu, Z.
    Wong, M.
    Rogerio, J.
    Garay, C.
    VALUE IN HEALTH, 2012, 15 (04) : A236 - A236
  • [24] Patient and healthcare practitioner preferences for treatments in advanced renal cell carcinoma
    Oliveira, N.
    Li, B. C. W.
    Kim, M.
    Park, I.
    Dsouza, A.
    Chua, S.
    Tan, E. M.
    Spiteri, C.
    Su, Y-L.
    Yang, C. K.
    Zhang, A.
    Wong, K. C. W.
    ANNALS OF ONCOLOGY, 2023, 34 : S1562 - S1562
  • [25] Patient preferences and expectations of systemic therapy in renal cell carcinoma.
    Battle, Dena
    Bergerot, Cristiane Decat
    Msaouel, Pavlos
    Jonasch, Eric
    Zhang, Tian
    George, Daniel J.
    Staehler, Michael D.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [26] Does presence of diabetes mellitus impact patient oncological outcomes in renal cell carcinoma: A multicenter analysis.
    Saidian, Ava
    Walia, Arman
    Patil, Dattatraya
    Saito, Kazutaka
    Patel, Devin
    Nguyen, Mimi Vu
    Chakoumakos, Madison
    Ghali, Fady
    Narasimhan, Rekha S.
    Perry, John M.
    Meagher, Margaret
    Yasuda, Yosuke
    Fujii, Yasuhisa
    Master, Viraj A.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [27] Latent class cluster analysis to understand heterogeneity in prostate cancer treatment utilities
    Meghani, Salimah H.
    Lee, Christopher S.
    Hanlon, Alexandra L.
    Bruner, Deborah W.
    BMC MEDICAL INFORMATICS AND DECISION MAKING, 2009, 9
  • [28] Treatment patterns and costs associated with axitinib and everolimus treatment for renal cell carcinoma: A retrospective health claims analysis.
    MacLean, Elizabeth A.
    Brown, Joshua
    Smith, Timothy W.
    Cisar, Laura A.
    Harnett, James
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [29] Exploring patient preference heterogeneity for pharmacological treatments for chronic pain: A latent class analysis
    Walsh, David A.
    Boeri, Marco
    Abraham, Lucy
    Atkinson, Jo
    Bushmakin, Andrew G.
    Cappelleri, Joseph C.
    Hauber, Brett
    Klein, Kathleen
    Russo, Leo
    Viktrup, Lars
    Turk, Dennis
    EUROPEAN JOURNAL OF PAIN, 2022, 26 (03) : 648 - 667
  • [30] Clear Cell Papillary Renal Cell Carcinoma: Clinicopathologic, Immunohistochemical, and Molecular Analysis.
    Duan, L.
    Youssef, R. F.
    Margulis, V.
    Lotan, Y.
    Koduru, P.
    Kabbani, W.
    Kapur, P.
    MODERN PATHOLOGY, 2011, 24 : 189A - 189A
12345